Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is an intravenous solution that provides electrolytes and calories. Dextrose serves as a source of calories and water for hydration. Electrolytes (sodium, potassium, magnesium, chloride, acetate) help maintain acid-base balance and osmotic pressure. Acetate is a bicarbonate precursor that helps correct metabolic acidosis.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
Parenteral replacement of fluid and electrolytes,Caloric supplementation in patients requiring IV therapy,Maintenance of hydration and electrolyte balance
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
Intravenous infusion; dose is individualized based on fluid and electrolyte requirements. Typical adult dose is 500-1000 m L per hour initially, then adjusted to clinical response.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Not applicable (isotonic solution components; glucose half-life ~1.5-2 h in healthy; electrolytes are distributed and excreted per homeostasis)
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Dextrose undergoes glycolysis and subsequent metabolism via the citric acid cycle. Electrolytes are not metabolized but are excreted or retained as needed by the kidneys. Acetate is metabolized in the liver and peripheral tissues to bicarbonate.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Renal: 90% (as water, electrolytes, and glucose), Fecal: <5%, Biliary: <1%
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
<5% (no significant binding; electrolytes and glucose are free)
Negligible for electrolytes and dextrose (<5%).
For water: ~0.6 L/kg (total body water); for electrolytes: variable (sodium ~0.4 L/kg, potassium ~0.5 L/kg); glucose ~0.2 L/kg
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Intravenous: 100%
Intravenous: 100%.
Contraindicated in severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia and metabolic acidosis. In mild-moderate impairment (GFR 30-89 m L/min), use with caution and monitor electrolytes, reduce infusion rate.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific adjustment for Child-Pugh class A or B. In severe hepatic impairment (Child-Pugh class C), use with caution due to risk of fluid overload and electrolyte imbalances; monitor closely.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Weight-based dosing: 10-20 m L/kg intravenously as a bolus for rehydration, then maintenance at 100-150 m L/kg/day for infants, 80-120 m L/kg/day for children, adjusted based on clinical status.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Elderly patients may have decreased renal function; use with caution, monitor renal function and electrolytes. Start at lower end of dose range (e.g., 100-500 m L/hour) and titrate slowly.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
Not for use in patients with known hypersensitivity to any component. Do not administer unless solution is clear and container undamaged. Discard unused portion.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy,Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hyperkalemia,Avoid rapid infusion to prevent hyperglycemia and osmotic diuresis,Risk of phlebitis and infection at injection site
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hyperkalemia,Hypernatremia,Hyperglycemia,Severe metabolic acidosis,Patients with known hypersensitivity to any component,Do not administer if solution is cloudy or contains precipitate
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No known direct food interactions. However, patients should maintain a balanced diet as recommended by their physician. Avoid excessive intake of potassium-rich foods or salt substitutes if at risk of hyperkalemia, especially with impaired renal function.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
No teratogenic risk in any trimester. Isolyte M with Dextrose 5% is a balanced electrolyte and glucose solution. Dextrose and electrolytes are endogenous substances; no fetal harm is expected with appropriate maternal administration. However, maternal hyperglycemia (e.g., from excessive dextrose) may cause fetal hyperinsulinism and rebound neonatal hypoglycemia, especially in third trimester.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Safe during breastfeeding. Dextrose and electrolytes are normal blood constituents. Glucose is actively transported into breast milk; M/P ratio approximately 1.0. No adverse effects on nursing infants expected.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
No dose adjustment required for pregnancy. Infusion rate should be guided by maternal fluid and electrolyte needs, blood glucose levels, and clinical status. During labor, monitor for fluid overload; consider reduced rate if oxytocin is co-administered. Increased glomerular filtration rate in pregnancy may necessitate adjustments in electrolyte compositions (e.g., potassium) but standard formulation remains appropriate.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
ISOLYTE M with dextrose 5% is a maintenance IV solution containing electrolytes and dextrose. Monitor serum electrolytes and glucose, especially in patients with renal impairment or diabetes. Do not administer simultaneously with blood through same tubing due to risk of hemolysis. Use inline filter if particulate contamination is suspected. Inspect for leaks and precipitate before administration. Adjust flow rate based on clinical status and fluid balance.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This solution provides fluids, sugar, and electrolytes to maintain body balance.,Inform your healthcare provider if you have diabetes, kidney problems, or heart disease.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat during infusion.,Avoid consuming extra salt or potassium without medical advice while receiving this treatment.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is an intravenous solution that provides electrolytes and calories. Dextrose serves as a source of calories and water for hydration. Electrolytes (sodium, potassium, magnesium, chloride, acetate) help maintain acid-base balance and osmotic pressure. Acetate is a bicarbonate precursor that helps correct metabolic acidosis.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose is individualized based on fluid and electrolyte requirements. Typical adult dose is 500-1000 m L per hour initially, then adjusted to clinical response.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No teratogenic risk in any trimester. Isolyte M with Dextrose 5% is a balanced electrolyte and glucose solution. Dextrose and electrolytes are endogenous substances; no fetal harm . ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.